News summary

Aptamer-engineered extracellular vesicles enable targeted celecoxib delivery for in vitro breast and colon cancer therapy

Source: Nature - Biotechnology • Published: 10 Nov 2026, 00:00

Summarized by Masters of Longevity from Nature - Biotechnology.

Aptamer‑coated EVs loaded with celecoxib increased anticancer effects in vitro.

Aptamer-engineered extracellular vesicles enable targeted celecoxib delivery for in vitro breast and colon cancer therapy
Key Takeaways
  • Aptamer‑EVs increased celecoxib uptake by MCF‑7 and HCT116 cells.
  • Cel‑apt‑EVs induced G0/G1 arrest and increased cancer cell apoptosis.
  • Findings are in vitro; efficacy in humans remains unproven.
Read the full article at Nature - Biotechnology ↗

Continue exploring

Recommended MoL Picks

MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.MoL PickMOTS-c: Where the Evidence EndsStudies offer clues about ageing and metabolism. What do they actually tell us about human health—and where does expert opinion take over?